Proteasome inhibitors in the treatment of nonsmall cell lung cancer: A systematic review of clinical evidence

BACKGROUND AND AIMS: Nonsmall cell lung cancer accounts for over 85% of lung cancer incidences worldwide, and often has a poor prognosis. Proteasome inhibitors, such as bortezomib, have previously demonstrated evidence in preclinical and clinical models in the treatment of NSCLC both alone and as pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Chua, Alethea Dasha Wenning, Thaarun, Thirumeninathan, Yang, Hui, Lee, Ainsley Ryan Yan Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Narrative Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643516/
https://www.ncbi.nlm.nih.gov/pubmed/38028684
http://dx.doi.org/10.1002/hsr2.1443

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643516/
https://www.ncbi.nlm.nih.gov/pubmed/38028684
http://dx.doi.org/10.1002/hsr2.1443

Ejemplares similares